Company Overview and News

0
Tabung Haji appoints Mohammed Nor as chairman, Zukri Samat as CEO

2018-07-13 theedgemarkets
KUALA LUMPUR (July 13): Lembaga Tabung Haji has appointed former Securities Commission executive chairman Tan Sri Mohammed Nor Md Yusof as its new chairman.
5258

0
Kenanga: Some bank stocks have undemanding valuations Kenanga: Several bank counters have undemanding valuations

2018-07-05 thestar.com.my
PETALING JAYA: The sentiment on Malaysia’s banking sector remains “neutral” in the second half of 2018, although several banking stocks continue to offer attractive value propositions.
HLFBF 1015 5258 1082 AMMHF

0
Local equity market looks positive over next 12 months, says AmInvestment Research

2018-07-04 theedgemarkets
KUALA LUMPUR (July 4): The outlook for the local equity market looks positive for the next twelve to eighteen months, backed by steady economic growth, according to AmInvestment Bank Research.
5258 PBLOF 5196 7237 1295

0
LTH group MD, deputy CEO leave

2018-07-03 thestar.com.my
PETALING JAYA: Lembaga Tabung Haji (LTH) has announced that group managing director and CEO Datuk Seri Johan Abdullah (pic) and deputy CEO Datuk Badlisyah Abdul Ghani have completed their two-year contract of service on June 30, 2018.
5258 7206

0
Tabung Haji announces departure of group MD and CEO, deputy CEO and two other board members

2018-07-03 theedgemarkets
KUALA LUMPUR (July 3): Lembaga Tabung Haji announced today the exit of its group managing director cum chief executive officer (CEO) Datuk Seri Johan Abdullah and the deputy CEO Datuk Badlisyah Abdul Ghani, as both have completed their two-year contract services at the pilgrim fund on June 30.
5258

17
Banking, aviation stocks remain favourites for foreign funds, says MIDF Research

2018-06-28 theedgemarkets
KUALA LUMPUR (June 28): Malaysian banking and aviation stocks were among the favourites for foreign funds, according to MIDF Amanah Investment Bank Bhd Research.
PBLOF MLYBY MLYNF 7113 8664 5681 TPGVF 6742 1295 5014 TGLVY 1155 5347 5258 YTLPF TNABY MYPRY TNABF GEBHF

20
Index-linked blue chips drag KLCI lower as regional markets slump

2018-06-28 theedgemarkets
KUALA LUMPUR (June 28): The FBM KLCI extended its losses early this morning, dragged by key index-linked blue chips, in line with slump at most regional markets.
KLKBY 2445 5347 5258 PBLOF TNABY 5819 4065 8621 TNABF 2836 1295

17
KLCI remains lacklustre, tracks subdued region

2018-06-21 theedgemarkets
KUALA LUMPUR (June 21): The FBM KLCI remained lacklustre at mid-morning today, tracking the subdued regional markets.
UPBMF 4065 5681 BATS 4162 2291 2089 7077 6033 0036 PNADF 4456 4863 5258 5819 MYTEF PNAGF

10
BIMB to restructure once dust settles at Tabung Haji

2018-06-20 theedgemarkets
BIMB Holdings Bhd will likely embark on a group restructuring next year at the earliest as it waits for the dust to settle at Lembaga Tabung Haji (TH) where there is currently a boardroom shake-up, sources say.
1155 1023 1015 5258 MLYBY 6139 MLYNF AMMHF BSMAF 1818 CIMDF

6
Net profit growth of 8.9% projected for banking sector for 2018

2018-06-19 theedgemarkets
Banking sector Maintain neutral: Although banks’ core net profit growth softened from 12.8% year-on-year (y-o-y) in the fourth quarter of 2017 (4Q17), the momentum remained healthy at 9.7% y-o-y in 1Q18. The key drivers of 1Q18 earnings growth were: i) a wider expansion of 8.3% y-o-y in non-interest income versus 7.7% y-o-y in 4Q17; ii) a 9.4% y-o-y drop in loan loss provisioning; and iii) a smaller increase of 1.
1015 5258 PBLOF AMMHF 1295

4
Trading ideas: CIMB, HLB, BIMB, MRCB, MyEG

2018-05-31 thestar.com.my
KUALA LUMPUR: JF Apex Research expects CIMB, Hong Leong Bank, BIMB Holdings Bhd and Malaysian Resources Corp Bhd and MyEG Services Bhd to be among the stocks to watch following their latest corporate results.
KPJHF 5258 5878 5819 5102 7155 5112

5
BIMB Holdings Q1 net profit rises to RM172.14mil

2018-05-31 thestar.com.my
Bank Islam's profit growth was mainly due to the increase in the base rate and base financing rate by 25 basis points effective February 2018, following the 25 basis points increase in overnight policy rate on Jan, 25, 2018, it said.
5258 BSMAF 1818

1
Maybank Islamic CEO Mohamed Rafique appointed IBFIM chairman

2018-03-29 themalaymailonline
Datuk Mohamed Rafique Merican, has been appointed Chairman of the Islamic Banking and Finance Institute of Malaysia’s (IBFIM) board of directors. — Bernama file picKUALA LUMPUR, March 29 — Maybank Islamic Bhd Chief Executive Officer (CEO), Datuk Mohamed Rafique Merican, has been appointed Chairman of the Islamic Banking and Finance Institute of Malaysia’s (IBFIM) board of directors effective yesterday.
5258

20
PNB funds reach RM279b, 98pc invested locally

2018-03-18 themalaymailonline
Tan Sri Abdul Wahid Omar said PNB is today Malaysia’s largest fund manager. — Picture by Zuraneeza ZulkifliKUALA LUMPUR, March 18 — Permodalan Nasional Bhd (PNB), established some 40 years ago, is today the country’s largest fund manager, managing funds worth RM279 billion, said its Group Chairman, Tan Sri Abdul Wahid Omar.
MLYBY MLYNF 4197 7148 1155 4588 4863 5347 5258 SMEBF TNABY 6459 6888 AXXTF MYTEF TNABF BSMAF 1818

10
Four decades on, PNB now Malaysia’s biggest fund manager

2018-03-17 themalaymailonline
PNB chairman Tan Sri Wahid Omar says the fund management firm has a war chest of RM279 billion. — Picture by Saw Siow FengKUALA LUMPUR, March 18 — Permodalan Nasional Bhd (PNB) has emerged as the country's biggest fund management firm with a war chest of RM279 billion, said Tan Sri Wahid Omar.
4588 5258 SMEBF 4197 BSMAF 1818

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...